MedTrace Logo

131I-rituximab for Relapsed or Refractory Follicular or Mantle Cell Lymphoma

NCT01678417 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2012-09-05

No results posted yet for this study

Summary

Follicular lymphoma (FL) and mantle cell lymphoma (MCL) are rare lymphomas which consist of less than 5% of non-Hodgkin lymphoma in Korea. Although FL with histologic grade 1 or 2 has relatively good prognosis, continual treatment is needed due to frequent relapse. FL with histologic grade 3 has poor prognosis similar to that of diffuse large B cell lymphoma. Meanwhile, the response rate to systemic chemotherapy in MCL is low, so the treatment of relapsed MCL is challenging. So we investigate the efficacy of radioimmunotherapy using 131I-rituximab in refractory or relapsed patients with FL or MCL

Conditions

  • Relapsed or Refractory Follicular Lymphoma or Mantle Cell Lymphoma

Interventions

DRUG

131I-rituximab

Sponsors & Collaborators

  • Korea Cancer Center Hospital

    lead OTHER

Principal Investigators

  • Hye Jin Kang, M.D. · Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2017-06-30
Completion
2017-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01678417 on ClinicalTrials.gov